According to the below, SERUM (blood) based DHT tests are not necessarily an accurate representation of true 5AR-II activity (at least in the prostate).
**** Testing for ADIOL-G is. ****
Although this mentions intraprostatic DHT, I would assume this would likely apply for circulating DHT outside of the prostate as well.
So on future bloodtests request ADIOL-G, in addition to DHT.
Association between Two Polymorphisms in the SRD5A2 Gene and Serum Androgen Concentrations in British Men
cebp.aacrjournals.org/cgi/content/full/12/6/578
"It is well established that the steroid 5 -reductase type II enzyme, which irreversibly converts testosterone to its more potent metabolite DHT3 in prostatic cells, is required for the normal growth and development of the prostate gland (1) .
A meta-analysis of prospective studies suggests that the serum concentration of A-diol-g, a serum marker of the abundance of 5 -reductase type II and intraprostatic DHT, is slightly higher in men who subsequently develop prostate cancer compared with healthy individuals (2) .
The circulating A-diol-g concentration is believed to be a more accurate serum marker of 5 -reductase type II than serum DHT itself, because A-diol-g is the direct metabolite of DHT formed in the prostate gland. However, circulating DHT is largely derived from 5 -reductase type I activity in the skin and is therefore not an accurate marker of intraprostatic 5 -reductase type II activity. "